comprehensive -WSS

comprehensive

author：focus 2025-09-27 09:40:02 - browse：36124

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Why Charlie Gard's case is so disturbing to Americans

knowledge

WSS

Was Amgen transparent enough on FDA's concern on cancer drug?

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

2 million sign

EU moves toward latest gene techniques in food production to counter climate change, shortages

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

VC firm General Catalyst wants to buy a health system

explore

comprehensive

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why Charlie Gard's case is so disturbing to Americans

In age of alternative facts, a scholarly course on calling out crap

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

In age of alternative facts, a scholarly course on calling out crap

Phenylephrine and the overlooked value of the placebo effect

Drug repurposing or repositioning? The language matters

5 shark bites reported on Long Island as officials deploy surveillance drones

Peter Hotez and the public health issue of online harassment

FDA rejects Alnylam's heart disease treatment over insufficient data

Wikipedia

Chemotherapy drug shortage eases slightly but still widespread

The leaders of Italy and Poland say European Union should focus on stopping migration

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

EU moves toward latest gene techniques in food production to counter climate change, shortages

Following judge's order, DOJ releases slightly less

VC firm General Catalyst wants to buy a health system

hotspot

knowledge

hotspot

Wikipedia